• 940 Citations
  • 17 Scopus h-Index
20052019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 2005 2019

Filter
Article
Article
1 Citation (Scopus)

Acute Disseminated Intravascular Coagulation after Oxaliplatin Infusion

Waddle, M., Irvin, M., Gupta, E., Gibbs, M., Kakar, T. S., Gannon, N. A., Arthurs, J. R., Fischer, D. L. & Ailawadhi, S., May 16 2017, (Accepted/In press) In : Chemotherapy. p. 295-300 6 p.

Research output: Contribution to journalArticle

oxaliplatin
Disseminated Intravascular Coagulation
Colorectal Neoplasms
Hypersensitivity
Pharmaceutical Preparations

AlternativeOutpatientChemotherapy scheduling method to improve patient service quality and nurse satisfaction

Huang, Y. L., Bryce, A. H., Culbertson, T., Connor, S. L., Looker, S. A., Altman, K. M., Collins, J. G., Stellner, W., Mc Williams, R. R., Moreno Aspitia, A., Ailawadhi, S. & Mesa, R. A., Feb 1 2018, In : Journal of Oncology Practice. 14, 2, p. e82-e91

Research output: Contribution to journalArticle

Nurses
Workload
Safety
Drug Therapy
Nursing Staff
5 Citations (Scopus)

A meta-analysis of multiple myeloma risk regions in African and European ancestry populations identifies putatively functional loci

Rand, K. A., Song, C., Dean, E., Serie, D. J., Curtin, K., Sheng, X., Hu, D., Huff, C. A., Bernal-Mizrachi, L., Tomasson, H. M., Ailawadhi, S., Singhal, S., Pawlish, K., Peters, E. S., Bock, C. H., Stram, A., Van Den Berg, D. J., Edlund, C. K., Conti, D. V., Zimmerman, T. & 82 others, Hwang, A. E., Huntsman, S., Graff, J., Nooka, A., Kong, Y., Pregja, S. L., Berndt, S. I., Blot, W. J., Carpten, J., Casey, G., Chu, L., Diver, W. R., Stevens, V. L., Lieber, M. R., Goodman, P. J., Hennis, A. J. M., Hsing, A. W., Mehta, J., Kittles, R. A., Kolb, S., Klein, E. A., Leske, C., Murphy, A. B., Nemesure, B., Neslund-Dudas, C., Strom, S. S., Vij, R., Rybicki, B. A., Stanford, J. L., Signorello, L. B., Witte, J. S., Ambrosone, C. B., Bhatti, P., John, E. M., Bernstein, L., Zheng, W., Olshan, A. F., Hu, J. J., Ziegler, R. G., Nyante, S. J., Bandera, E. V., Birmann, B. M., Ingles, S. A., Press, M. F., Atanackovic, D., Glenn, M. J., Cannon-Albright, L. A., Jones, B., Tricot, G., Martin, T. G., Kumar, S. K., Wolf, J. L., Deming Halverson, S. L., Rothman, N., Brooks-Wilson, A. R., Rajkumar, S. V., Kolonel, L. N., Chanock, S. J., Slager, S. L., Severson, R. K., Janakiraman, N., Terebelo, H. R., Brown, E. E., De Roos, A. J., Mohrbacher, A. F., Colditz, G. A., Giles, G. G., Spinelli, J. J., Chiu, B. C., Munshi, N. C., Anderson, K. C., Levy, J., Zonder, J. A., Orlowski, R. Z., Lonial, S., Camp, N. J., Vachon, C. M., Ziv, E., Stram, D. O., Hazelett, D. J., Haiman, C. A. & Cozen, W., Dec 1 2016, In : Cancer Epidemiology Biomarkers and Prevention. 25, 12, p. 1609-1618 10 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Meta-Analysis
Population
NF-kappa B
Tumor Necrosis Factor Receptors
4 Citations (Scopus)

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Ailawadhi, S., Kelly, K. R., Vescio, R. A., Jagannath, S., Wolf, J., Gharibo, M., Sher, T., Bojanini, L., Kirby, M. & Chanan Khan, A. A., Jan 1 2018, (Accepted/In press) In : Clinical Lymphoma, Myeloma and Leukemia.

Research output: Contribution to journalArticle

Multiple Myeloma
Pharmacokinetics
Safety
Maximum Tolerated Dose
Clinical Trials, Phase I
gemcitabine
Cholangiocarcinoma
Cisplatin
Epidemiology
Survival
11 Citations (Scopus)

A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients

Sher, T., Ailawadhi, S., Miller, K. C., Manfredi, D., Wood, M., Tan, W., Wilding, G., Czuczman, M. S., Hernandez-Ilizaliturri, F. J., Hong, F., Sood, R., Soniwala, S., Lawrence, W., Jamshed, S., Masood, A., Iancu, D., Lee, K. & Chanan Khan, A. A., Jul 2011, In : British Journal of Haematology. 154, 1, p. 104-110 7 p.

Research output: Contribution to journalArticle

Thalidomide
Multiple Myeloma
Steroids
Drug Combinations
Constipation
10 Citations (Scopus)

Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia

Paludo, J., Abeykoon, J. P., Shreders, A., Ansell, S. M., Kumar, S. K., Ailawadhi, S., King, R., Koehler, A. B., Reeder, C. B., Buadi, F. K., Dispenzieri, A., Lacy, M., Dingli, D. M., Witzig, T. E., Go, R. S., Gonsalves, W., Kourelis, T., Warsame, R., Leung, N., Habermann, T. M. & 6 others, Hayman, S., Lin, Y., Kyle, R. A., Rajkumar, S. V., Gertz, M. & Kapoor, P., Apr 3 2018, (Accepted/In press) In : Annals of Hematology. p. 1-9 9 p.

Research output: Contribution to journalArticle

Waldenstrom Macroglobulinemia
Cyclophosphamide
Dexamethasone
Disease-Free Survival
Bendamustine Hydrochloride
25 Citations (Scopus)

Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: Results of a phase II clinical trial

Chanan Khan, A. A., Miller, K. C., Musial, L., Padmanabhan, S., Yu, J., Ailawadhi, S., Sher, T., Mohr, A., Bernstein, Z. P., Barcos, M., Patel, M., Iancu, D., Lee, K. & Czuczman, M. S., 2009, In : Leukemia and Lymphoma. 50, 7, p. 1096-1101 6 p.

Research output: Contribution to journalArticle

Phase II Clinical Trials
Thalidomide
Multiple Myeloma
Steroids
Plasma Cells
13 Citations (Scopus)

Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma

Ailawadhi, S., Miecznikowski, J., Gaile, D. P., Wang, D., Sher, T., Mulligan, G., Bryant, B., Wilding, G. E., Mashtare, T., Stein, L., Masood, A., Neuwirth, R., Lee, K. P. & Chanan Khan, A. A., Jun 2012, In : Leukemia and Lymphoma. 53, 6, p. 1174-1182 9 p.

Research output: Contribution to journalArticle

Multiple Myeloma
bcl-2 Genes
Apoptosis Regulatory Proteins
Dexamethasone
Proteins
26 Citations (Scopus)

Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer

Ailawadhi, S., Sunga, A., Rajput, A., Yang, G. Y., Smith, J. & Fakih, M., Mar 2006, In : Oncology. 70, 1, p. 49-53 5 p.

Research output: Contribution to journalArticle

Carcinoembryonic Antigen
Colorectal Neoplasms
Drug Therapy
Incidence
Neoplasms
15 Citations (Scopus)

Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells

Paulus, A., Akhtar, S., Caulfield, T., Samuel, K., Yousaf, H., Bashir, Y., Paulus, S. M., Tran, D., Hudec, R., Cogen, D., Jiang, J., Edenfield, B., Novak, A. J., Ansell, S. M., Witzig, T. E., Martin, P., Coleman, M., Roy, V., Ailawadhi, S., Chitta, K. & 2 others, Linder, S. & Chanan Khan, A. A., Nov 4 2016, In : Blood Cancer Journal. 6, 11, e492.

Research output: Contribution to journalArticle

Ubiquitin-Specific Proteases
Waldenstrom Macroglobulinemia
Hydrolases
Ubiquitin
Isoenzymes
2 Citations (Scopus)

Correlation of sociodemographic and clinical parameters with depression and distress in patients with hematologic malignancies

Shreders, A. J., Niazi, S. K., Hodge, D. O., Chimato, N. T., Kureti, M., Kirla, N., Agrawal, A., Swaika, A., Gustetic, E., Foster, R., Nelson, K. A., Jani, P., Chanan Khan, A. A. & Ailawadhi, S., Dec 7 2017, (Accepted/In press) In : Annals of Hematology. p. 1-10 10 p.

Research output: Contribution to journalArticle

Hematologic Neoplasms
Thermometers
Nonparametric Statistics
Health
Psychiatry
8 Citations (Scopus)

Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States

Jakubowiak, A. J., Houisse, I., Májer, I., Benedict, Á., Campioni, M., Panjabi, S. & Ailawadhi, S., Dec 2 2017, In : Expert Review of Hematology. 10, 12, p. 1107-1119 13 p.

Research output: Contribution to journalArticle

Quality-Adjusted Life Years
Multiple Myeloma
Dexamethasone
Cost-Benefit Analysis
Costs and Cost Analysis
8 Citations (Scopus)

Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States

Pelligra, C. G., Parikh, K., Guo, S., Chandler, C., Mouro, J., Abouzaid, S. & Ailawadhi, S., 2017, (Accepted/In press) In : Clinical Therapeutics.

Research output: Contribution to journalArticle

Multiple Myeloma
Cost-Benefit Analysis
Quality-Adjusted Life Years
Health Care Costs
Costs and Cost Analysis

Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma

Ailawadhi, S., DerSarkissian, M., Duh, M. S., Lafeuille, M. H., Posner, G., Ralston, S., Zagadailov, E., Ba-Mancini, A. & Rifkin, R., Jan 1 2019, In : Clinical therapeutics.

Research output: Contribution to journalArticle

Multiple Myeloma
Costs and Cost Analysis
Therapeutics
Dexamethasone
Subcutaneous Infusions
1 Citation (Scopus)

Deep sequencing reveals lack of a clonal relationship between a metachronous classical hodgkin and diffuse large B-cell lymphoma

Siddiqi, I. N., Ailawadhi, S., Huang, Q., Shibata, R. K., Kang, H. & Shibata, D., 2014, In : Clinical Lymphoma, Myeloma and Leukemia. 14, 3

Research output: Contribution to journalArticle

Clonal Evolution
High-Throughput Nucleotide Sequencing
Lymphoma, Large B-Cell, Diffuse
Hodgkin Disease
Young Adult
16 Citations (Scopus)

Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute- Waldenström Macroglobulinemia 1

Chitta, K. S., Paulus, A., Ailawadhi, S., Foster, B. A., Moser, M. T., Starostik, P., Masood, A., Sher, T., Miller, K. C., Iancu, D. M., Conroy, J., Nowak, N. J., Sait, S. N., Personett, D. A., Coleman, M., Furman, R. R., Martin, P., Ansell, S. M., Lee, K. & Chanan Khan, A. A., Feb 2013, In : Leukemia and Lymphoma. 54, 2, p. 387-396 10 p.

Research output: Contribution to journalArticle

Waldenstrom Macroglobulinemia
Cell Line
Neoplasms
Immunoglobulin Heavy Chains
Tumor Cell Line
6 Citations (Scopus)

Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia

Paludo, J., Abeykoon, J. P., Kumar, S. K., Shreders, A., Ailawadhi, S., Gertz, M., Kourelis, T., King, R., Reeder, C. B., Leung, N., Kyle, R. A., Buadi, F. K., Habermann, T. M., Dingli, D. M., Witzig, T. E., Dispenzieri, A., Lacy, M., Go, R. S., Lin, Y., Gonsalves, W. & 5 others, Warsame, R., Lust, J. A., Rajkumar, S. V., Ansell, S. M. & Kapoor, P., Oct 1 2017, In : British Journal of Haematology. 179, 1, p. 98-105 8 p.

Research output: Contribution to journalArticle

Waldenstrom Macroglobulinemia
Cyclophosphamide
Dexamethasone
Confidence Intervals
Disease-Free Survival
43 Citations (Scopus)
Waldenstrom Macroglobulinemia
Guidelines
Stem Cell Transplantation
Therapeutics
Clinical Trials
4 Citations (Scopus)

Disease and outcome disparities in multiple myeloma: Exploring the role of race/ethnicity in the Cooperative Group clinical trials

Ailawadhi, S., Jacobus, S., Sexton, R., Stewart, A. K., Dispenzieri, A., Hussein, M. A., Zonder, J. A., Crowley, J., Hoering, A., Barlogie, B., Orlowski, R. Z. & Rajkumar, S. V., Jul 1 2018, In : Blood Cancer Journal. 8, 7, 67.

Research output: Contribution to journalArticle

Multiple Myeloma
Clinical Trials
Anemia
Therapeutics
Survival
18 Citations (Scopus)

Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner

Masood, A., Chitta, K., Paulus, A., Khan, A. N. H., Sher, T., Ersing, N., Miller, K. C., Manfredi, D., Ailawadhi, S., Borrelo, I., Lee, K. P. & Chanan Khan, A. A., Apr 2012, In : British Journal of Haematology. 157, 1, p. 59-66 8 p.

Research output: Contribution to journalArticle

B-Cell Chronic Lymphocytic Leukemia
Down-Regulation
Therapeutics
Antibodies
Immunologic Factors
4 Citations (Scopus)

Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?

Ailawadhi, S., Bhatia, K., Aulakh, S., Meghji, Z. & Chanan Khan, A. A., Jun 19 2017, (Accepted/In press) In : Current Hematologic Malignancy Reports. p. 1-8 8 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Delivery of Health Care
Geographic Locations
Insurance Carriers
Vulnerable Populations
9 Citations (Scopus)

Erlotinib for metastatic non-small-cell lung cancer: First-, second- or third-line setting - Does it matter? A single-institution experience

Ailawadhi, S., Derby, L., Natarajan, R., Fetterly, G., Reid, M. & Ramnath, N., Feb 2009, In : Oncology. 76, 2, p. 85-90 6 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Survival
Erlotinib Hydrochloride
Therapeutics
Prescriptions
13 Citations (Scopus)

Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma

Ailawadhi, S., Abdelhalim, A. N., Derby, L., Mashtare, T. L., Miller, K. C., Wilding, G. E., Alberico, R. A., Gottlieb, R., Klippenstein, D. L., Lee, K. & Chanan Khan, A. A., Jan 1 2010, In : Cancer. 116, 1, p. 84-92 9 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Bone Marrow
Magnetic Resonance Imaging
Survival
Salmon
7 Citations (Scopus)

Extramedullary solitary plasmacytoma: Demonstrating the role of 18F-FDG PET imaging

Gautam, A., Sahu, K. K., Alamgir, A., Siddiqi, I. & Ailawadhi, S., Apr 1 2017, In : Journal of Clinical and Diagnostic Research. 11, 4, p. XD01-XD03

Research output: Contribution to journalArticle

Plasmacytoma
Fluorodeoxyglucose F18
Plasmas
Imaging techniques
Plasma Cells
14 Citations (Scopus)

Financial burden after allogeneic hematopoietic cell transplantation: A qualitative analysis from the patient's perspective

Kim, W., McNulty, J., Chang, Y. H., Weise, M., Hashmi, S., Ailawadhi, S. & Khera, N. D., Sep 4 2015, In : Bone Marrow Transplantation. 50, 9, p. 1259-1261 3 p.

Research output: Contribution to journalArticle

51 Citations (Scopus)

IAP antagonists induce anti-tumor immunity in multiple myeloma

Chesi, M., Mirza, N. N., Garbitt, V. M., Sharik, M. E., Dueck, A., Asmann, Y., Akhmetzyanova, I., Kosiorek, H. E., Calcinotto, A., Riggs, D. L., Keane, N., Ahmann, G. J., Morrison, K. M., Fonseca, R., Lacy, M., Dingli, D. M., Kumar, S. K., Ailawadhi, S., Dispenzieri, A., Buadi, F. & 7 others, Gertz, M., Reeder, C. B., Lin, Y., Chanan Khan, A. A., Stewart, A. K., Fooksman, D. & Bergsagel, P. L., Dec 1 2016, In : Nature Medicine. 22, 12, p. 1411-1420 10 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Tumors
Immunity
Apoptosis
Neoplasms
6 Citations (Scopus)

Immunophenotyping of Waldenströms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: Potential biological and therapeutic implications

Paulus, A., Chitta, K. S., Wallace, P. K., Advani, P. P., Akhtar, S., Kuranz-Blake, M., Ailawadhi, S. & Chanan Khan, A. A., Apr 8 2015, In : PLoS One. 10, 4, e0122338.

Research output: Contribution to journalArticle

Waldenstrom Macroglobulinemia
Immunophenotyping
surface antigens
Surface Antigens
Cells
8 Citations (Scopus)

Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis

Ailawadhi, S., Advani, P., Yang, D., Ghosh, R., Swaika, A., Roy, V., Foran, J. M., Colon-Otero, G. & Chanan Khan, A. A., Feb 15 2016, In : Cancer. 122, 4, p. 618-625 8 p.

Research output: Contribution to journalArticle

National Cancer Institute (U.S.)
Multiple Myeloma
Registries
Neoplasms
Survival

Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma

Niazi, S., Frank, R. D., Sharma, M., Roy, V., Ames, S., Rummans, T., Spaulding, A., Sher, T., Ailawadhi, M., Bhatia, K., Ahmed, S., Tan, W., Chanan Khan, A. A. & Ailawadhi, S., May 22 2018, In : Blood advances. 2, 10, p. 1120-1128 9 p.

Research output: Contribution to journalArticle

Patient Acceptance of Health Care
Multiple Myeloma
Health Care Costs
Psychiatry
Comorbidity
3 Citations (Scopus)

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma

Jagannath, S., Heffner, L. T., Ailawadhi, S., Munshi, N. C., Zimmerman, T. M., Rosenblatt, J., Lonial, S., Chanan Khan, A. A., Ruehle, M., Rharbaoui, F., Haeder, T., Wartenberg-Demand, A. & Anderson, K. C., Jan 1 2019, In : Clinical Lymphoma, Myeloma and Leukemia.

Research output: Contribution to journalArticle

Multiple Myeloma
Appointments and Schedules
Neoplasms

Influence of Sociodemographic Factors on Treatment Decisions in Non–Small-Cell Lung Cancer

Duma, N., Idossa, D. W., Durani, U., Frank, R. D., Paludo, J., Westin, G., Lou, Y., Mansfield, A. S., Adjei, A. A., Go, R. S. & Ailawadhi, S., Jan 1 2019, (Accepted/In press) In : Clinical Lung Cancer.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Treatment Refusal
Drug Therapy
Therapeutics
Radiotherapy
3 Citations (Scopus)

Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma

Ailawadhi, S., Nagase, H., Khoury, T., Yu, J., Tan, D., Black, J., Brattain, M. & Javle, M., Jul 2007, In : Hepato-Gastroenterology. 54, 77, p. 1339-1344 6 p.

Research output: Contribution to journalArticle

Cholangiocarcinoma
Extracellular Signal-Regulated MAP Kinases
Biliary Tract Neoplasms
Epidemiology
Cytoprotection

Marantic endocarditis associated with T-Cell large granular lymphocytic leukemia: First report of its occurrence with a lymphoproliferative malignancy in adults

Ahmed, S., Jani, P., Yamani, M. H., Ailawadhi, S., Alegria, V. R. & Ailawadhi, M., Oct 1 2018, In : Journal of Oncology Practice. 14, 10, p. 625-627 3 p.

Research output: Contribution to journalArticle

Non-Infective Endocarditis
Large Granular Lymphocytic Leukemia
Neoplasms

Monoclonal antibody utilization characteristics in patients with multiple myeloma

Ailawadhi, S., Sher, T., Azzouqa, A. G., Meghji, Z., Jain, T., Jani, P., Ahmed, S., Diehl, N., Roy, V., Shah, V., Hodge, D., Ailawadhi, M., Alegria, V. R., Paulus, A., Chanan Khan, A. A. & Fonseca, R., Sep 1 2019, In : Anti-cancer drugs. 30, 8, p. 859-865 7 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Monoclonal Antibodies
Premedication
Clinical Trials
Drug Utilization
13 Citations (Scopus)

Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia

Chitta, K., Paulus, A., Caulfield, T., Akhtar, S., Blake, M. K. K., Ailawadhi, S., Knight, J., Heckman, M. G., Pinkerton, A. & Chanan Khan, A. A., Jan 1 2014, In : Blood Cancer Journal. 4, 11, e260.

Research output: Contribution to journalArticle

Waldenstrom Macroglobulinemia
Apoptosis
Limonins
Neoplasms
Computer Simulation
11 Citations (Scopus)

Outcome disparities among ethnic subgroups of waldenström's macroglobulinemia: A population-based study

Ailawadhi, S., Kardosh, A., Yang, D., Cozen, W., Patel, G., Alamgir, M. A. & Chanan Khan, A. A., 2014, In : Oncology (Switzerland). 86, 5-6, p. 253-262 10 p.

Research output: Contribution to journalArticle

Waldenstrom Macroglobulinemia
African Americans
Population
Health Resources
Marital Status
39 Citations (Scopus)

Outcome disparities in multiple myeloma: A SEER-based comparative analysis of ethnic subgroups

Ailawadhi, S., Aldoss, I. T., Yang, D., Razavi, P., Cozen, W., Sher, T. & Chanan Khan, A. A., Jul 2012, In : British Journal of Haematology. 158, 1, p. 91-98 8 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Epidemiology
Survival
Hispanic Americans
Registries

Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma

Ailawadhi, S., Dholaria, B. R., Khurana, S., Sher, T., Alegria, V., Paulus, A., Ailawadhi, M., Mehta, A., Chanan Khan, A. A. & Roy, V., Jan 1 2018, (Accepted/In press) In : British Journal of Haematology.

Research output: Contribution to journalArticle

B-Cell Chronic Lymphocytic Leukemia
Multiple Myeloma
2 Citations (Scopus)

Palliative Care Use Among Patients With Solid Cancer Tumors: A National Cancer Data Base Study

Osagiede, O., Colibaseanu, D. T., Spaulding, A., Frank, R. D., Merchea, A., Kelley, S. R., Uitti, R. J. & Ailawadhi, S., Jan 1 2018, (Accepted/In press) In : Journal of Palliative Care.

Research output: Contribution to journalArticle

Palliative Care
Databases
Neoplasms
Lung Neoplasms
Melanoma
32 Citations (Scopus)

Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics

Razavi, P., Rand, K. A., Cozen, W., Chanan Khan, A. A., Usmani, S. & Ailawadhi, S., Jun 2013, In : Blood Cancer Journal. 3, 6, e121.

Research output: Contribution to journalArticle

Second Primary Neoplasms
Multiple Myeloma
Confidence Intervals
Therapeutics
Incidence
10 Citations (Scopus)
Lymphoma, Large B-Cell, Diffuse
T-Cell Lymphoma
Non-Hodgkin's Lymphoma
Epidemiology
B-Lymphocytes
10 Citations (Scopus)

Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma

Kim, M. Y., Sposto, R., Swaika, A., Asano, H., Alamgir, A., Chanan Khan, A. A. & Ailawadhi, S., Nov 7 2014, In : Oncology (Switzerland). 87, 4, p. 224-231 8 p.

Research output: Contribution to journalArticle

Pharmaceutical Economics
Melphalan
Multiple Myeloma
Prednisone
Costs and Cost Analysis

Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies

Siddiqi, T., Frankel, P., Beumer, J. H., Kiesel, B. F., Christner, S., Ruel, C., Song, J. Y., Chen, R., Kelly, K. R., Ailawadhi, S., Kaesberg, P., Popplewell, L., Puverel, S., Piekarz, R., Forman, S. J. & Newman, E. M., Jan 1 2019, (Accepted/In press) In : Leukemia and Lymphoma.

Research output: Contribution to journalArticle

Aurora Kinase A
Histone Deacetylase Inhibitors
Neoplasms
Appointments and Schedules
vorinostat
1 Citation (Scopus)

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Stewart, A. K., Krishnan, A. Y., Singhal, S., Boccia, R. V., Patel, M. R., Niesvizky, R., Chanan Khan, A. A., Ailawadhi, S., Brumm, J., Mundt, K. E., Hong, K., McBride, J., Shon-Nguyen, Q., Xiao, Y., Ramakrishnan, V., Polson, A. G., Samineni, D., Leipold, D., Humke, E. W., McClellan, J. S. & 1 others, Berdeja, J. G., Feb 1 2019, In : Blood cancer journal. 9, 2, 17.

Research output: Contribution to journalArticle

Open Access
Multiple Myeloma
Anti-Idiotypic Antibodies
Maximum Tolerated Dose
Antibodies
Pharmaceutical Preparations
23 Citations (Scopus)

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma

Paludo, J., Mikhael, J. R., Laplant, B. R., Halvorson, A. E., Kumar, S. K., Gertz, M., Hayman, S. R., Buadi, F. K., Dispenzieri, A., Lust, J. A., Kapoor, P., Leung, N., Russell, S. J., Dingli, D. M., Go, R. S., Lin, Y., Gonsalves, W., Fonseca, R., Bergsagel, P. L., Roy, V. & 8 others, Sher, T., Chanan Khan, A. A., Ailawadhi, S., Stewart, A. K., Reeder, C. B., Richardson, P. G., Rajkumar, S. V. & Lacy, M., Sep 7 2017, In : Blood. 130, 10, p. 1198-1204 7 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Refractory materials
Dexamethasone
Toxicity
Physical vapor deposition
8 Citations (Scopus)

Pomalidomide-dexamethasone in refractory multiple myeloma: Long-term follow-up of a multi-cohort phase II clinical trial

Ailawadhi, S., Mikhael, J. R., Laplant, B. R., Laumann, K. M., Kumar, S. K., Roy, V., Dingli, D. M., Bergsagel, P. L., Buadi, F. K., Rajkumar, S. V., Fonseca, R., Gertz, M., Kapoor, P., Sher, T., Hayman, S. R., Stewart, A. K., Dispenzieri, A., Kyle, R. A., Gonsalves, W., Reeder, C. B. & 8 others, Lin, Y., Go, R. S., Leung, N., Kourelis, T., Lust, J. A., Russell, S. J., Chanan Khan, A. A. & Lacy, M., Mar 1 2018, In : Leukemia. 32, 3, p. 719-728 10 p.

Research output: Contribution to journalArticle

Phase II Clinical Trials
Multiple Myeloma
Dexamethasone
Appointments and Schedules
Therapeutics

Predictors of palliative treatment in stage IV colorectal cancer

Osagiede, O., Spaulding, A., Frank, R. D., Merchea, A., Uitti, R., Ailawadhi, S., Kelley, S. & Colibaseanu, D., Jan 1 2018, (Accepted/In press) In : American Journal of Surgery.

Research output: Contribution to journalArticle

Palliative Care
Colorectal Neoplasms
Survival
Medicaid
Quality of Life

Prevalence of BCL-2/J(H) Translocation in Healthy African Americans

Colon-Otero, G., Van Wier, S. A., Ahmann, G. J., Braggio, E. D., Albertie, M. L., Weis, J. A., Ailawadhi, S., Cerhan, J. R., Vishnu, P., Jorgensen, M. S., Foran, J. M., Thomas, C. S. & Fonseca, R., Jan 1 2017, In : Annals of Hematology. 96, 1, p. 51-55 5 p.

Research output: Contribution to journalArticle

African Americans
Follicular Lymphoma
Lymphocytes
Polymerase Chain Reaction
DNA

Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: A SEER-Medicare analysis

Ailawadhi, S., Parikh, K., Abouzaid, S., Zhou, Z., Tang, W., Clancy, Z., Cheung, C., Zhou, Z. Y. & Xie, J., Oct 22 2019, In : Blood Advances. 3, 20, p. 2986-2994 9 p.

Research output: Contribution to journalArticle

Open Access
Medicare
Multiple Myeloma
Epidemiology
Hispanic Americans
African Americans